Physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid: A review

[en] Ellagic acid (EA) is a polyphenolic active compound with antimalarial and other promising therapeutic activities. However, its solubility and its permeability are both low (BCS IV). These properties greatly compromise its oral bioavailability and clinical utilizations. To overcome these limitations of the physicochemical parameters, several formulation approaches, including particle size reduction, amorphization and lipid-based formulations, have been used. Although these strategies have not yet led to a clinical application, some of them have resulted in significant improvements in the solubility and bioavailability of EA. This critical review reports and analyses the different formulation approaches used by scientists to improve both the biopharmaceutical properties and the clinical use of EA.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Nyamba, Isaïe ; Université de Liège - ULiège > CIRM

Lechanteur, Anna ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Semdé, Rasmé; université joseph ki-zerbo > Pharmacie

Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Language :

English

Title :

Physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid: A review

Alternative titles :

[en] European journal of pharmaceutics and biopharmaceutics

Publication date :

07 November 2020

Journal title :

European Journal of Pharmaceutics and Biopharmaceutics

ISSN :

0939-6411

eISSN :

1873-3441

Publisher :

Elsevier, Amsterdam, Netherlands

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 December 2020

Statistics

Number of views

122 (12 by ULiège)

Number of downloads

623 (8 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Tambosi, G., Coelho, P.F., Soares, L., Lenschow, I.C.S., Zétola, M., Stulzer, H.K., Pezzini, B.R., Challenges to improve the biopharmaceutical properties of poorly water-soluble drugs and the application of the solid dispersion technology. Rev. Mater., 23, 2018, 10.1590/s1517-707620180004.0558.
Malaquias, L.F.B., Schulte, H.L., Chaker, J.A., Karan, K., Durig, T., Marreto, R.N., Gratieri, T., Gelfuso, G.M., Cunha-Filho, M., Hot Melt Extrudates Formulated Using Design Space: One Simple Process for Both Palatability and Dissolution Rate Improvement. J. Pharm. Sci. 107 (2018), 286–296, 10.1016/j.xphs.2017.08.014.
Koch, N., Jennotte, O., Grignard, B., Lechanteur, A., Evrard, B., Impregnation of mesoporous silica with poor aqueous soluble molecule using pressurized carbon dioxide: is the solubility in the supercritical and subcritical phase a critical parameter?. Eur. J. Pharm. Sci., 2020, 105332, 10.1016/j.ejps.2020.105332.
Ghadi, R., Dand, N., BCS class IV drugs: Highly notorious candidates for formulation development. J. Control. Release. 248 (2017), 71–95, 10.1016/j.jconrel.2017.01.014.
Alfei, S., Turrini, F., Catena, S., Zunin, P., Grilli, M., Pittaluga, A.M., Boggia, R., Ellagic acid a multi-target bioactive compound for drug discovery in CNS? A narrative review. Eur. J. Med. Chem., 183, 2019, 111724, 10.1016/j.ejmech.2019.111724.
García-Niño, W.R., Zazueta, C., Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. Pharmacol. Res. 97 (2015), 84–103, 10.1016/j.phrs.2015.04.008.
Larrosa, M., García-Conesa, M.T., Espín, J.C., Tomás-Barberán, F.A., Ellagitannins, ellagic acid and vascular health. Mol. Aspects Med. 31 (2010), 513–539, 10.1016/j.mam.2010.09.005.
Dhooghe, L., Meert, H., Cimanga, R.K., Vlietinck, A.J., Pieters, L., Apers, S., The quantification of ellagic acid in the crude extract of Phyllanthus amarus Schum. & Thonn. (Euphorbiaceae). Phytochem. Anal. 22 (2011), 361–366, 10.1002/pca.1288.
Zeb, A., Ellagic acid in suppressing in vivo and in vitro oxidative stresses. Mol. Cell. Biochem. 448 (2018), 27–41, 10.1007/s11010-018-3310-3.
Polonorum, A.S., Lipinska, L., Klewicka, E., Ellagitannins: a General Review *, Acta Sci. Pol., Technol. Aliment. 13 (2014), 289–299, 10.17306/J.AFS.2014.3.7.
Fukushima, Y., Ohie, T., Yonekawa, Y., Yonemoto, K., Aizawa, H., Mori, Y., Watanabe, M., Takeuchi, M., Hasegawa, M., Taguchi, C., Kondo, K., Coffee and green tea as a large source of antioxidant polyphenols in the Japanese population. J. Agric. Food Chem. 57 (2009), 1253–1259, 10.1021/jf802418j.
Ahmed, T., Setzer, W.N., Fazel Nabavi, S., Erdogan Orhan, I., Braidy, N., Sobarzo-Sanchez, E., Mohammad Nabavi, S., Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review. Curr. Pharm. Des. 22 (2016), 1350–1360, 10.2174/1381612822666160125114503.
Kang, I., Buckner, T., Shay, N.F., Gu, L., Chung, S., Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and, 2016, 961–972, 10.3945/an.116.012575.961.
Landete, J.M., Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health. Food Res. Int. 44 (2011), 1150–1160, 10.1016/j.foodres.2011.04.027.
Kang, I., Buckner, T., Shay, N.F., Gu, L., Chung, S., Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and Mechanisms. Adv. Nutr. 7 (2016), 961–972, 10.3945/an.116.012575.
Ríos, J.L., Giner, R.M., Marín, M., Recio, M.C., A Pharmacological Update of Ellagic Acid. Planta Med. 84 (2018), 1068–1093, 10.1055/a-0633-9492.
Soh, P.N., Witkowski, B., Olagnier, D., Nicolau, M.L., Garcia-Alvarez, M.C., Berry, A., Benoit-Vical, F., In vitro and in vivo properties of ellagic acid in malaria treatment. Antimicrob. Agents Chemother. 53 (2009), 1100–1106, 10.1128/AAC.01175-08.
Goudarzi, M., Mombeini, M.A., Fatemi, I., Aminzadeh, A., Kalantari, H., Nesari, A., Najafzadehvarzi, H., Mehrzadi, S., Neuroprotective effects of Ellagic acid against acrylamide-induced neurotoxicity in rats. Neurol. Res. 41 (2019), 419–428, 10.1080/01616412.2019.1576319.
Wang, Y., Qiu, Z., Zhou, B., Liu, C., Ruan, J., Yan, Q., Liao, J., Zhu, F., In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells. Toxicol. Vitr. 29 (2015), 1107–1115, 10.1016/j.tiv.2015.04.008.
Kaneto, H., Katakami, N., Matsuhisa, M., Matsuoka, T.A., Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm., 2010, 2010, 10.1155/2010/453892.
X. Yang, F.A. Toma, Tea Is a Signi fi cant Dietary Source of Ellagitannins and Ellagic Acid ́, (2019). 10.1021/acs.jafc.8b05010.
Alfei, S., Alfei, S., Turrini, F., Catena, S., Zunin, P., Zuccari, G., Pittaluga, A.M., Preparation of ellagic acid micro and nano formulations with amazingly increased water solubility by its entrapment in pectin or non-PAMAM dendrimers suitable for clinical applications. New J. Chem. 43 (2019), 2438–2448, 10.1039/C8NJ05657A.
J. Fotie, ChemInform Abstract: The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate, ChemInform. 42 (2011) no-no. 10.1002/chin.201105244.
Kilic, I., Yeşiloǧlu, Y., Bayrak, Y., Spectroscopic studies on the antioxidant activity of ellagic acid, Spectrochim. Acta - Part A Mol. Biomol. Spectrosc. 130 (2014), 447–452, 10.1016/j.saa.2014.04.052.
Salminen, J.-P., Seasonal Variation in the Bacterial Content of Oysters. Am. J. Public Health. 2 (2004), 24–27, 10.2105/ajph.2.1.24.
Celik, G., Semiz, A., Karakurt, S., Arslan, S., Adali, O., Sen, A., Erratum to “A comparative study for the evaluation of two doses of ellagic acid on hepatic drug metabolizing and antioxidant enzymes in the rat”. Biomed Res. Int., 2014, 2014, 10.1155/2014/476290.
Hseu, Y.C., Chou, C.W., Senthil Kumar, K.J., Fu, K.T., Wang, H.M., Hsu, L.S., Kuo, Y.H., Wu, C.R., Chen, S.C., Yang, H.L., Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food Chem. Toxicol. 50 (2012), 1245–1255, 10.1016/j.fct.2012.02.020.
Hussein, M.Z., Al Ali, S.H., Zainal, Z., Hakim, M.N., Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent. Int. J. Nanomedicine. 6 (2011), 1373–1383, 10.2147/ijn.s21567.
D.V. Ratnam, D.D. Ankola, V. Bhardwaj, D.K. Sahana, M.N.V.R. Kumar, Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective, 113 (2006) 189–207. 10.1016/j.jconrel.2006.04.015.
Bala, I., Bhardwaj, V., Hariharan, S., Kumar, M.N.V.R., Analytical methods for assay of ellagic acid and its solubility studies. J. Pharm. Biomed. Anal. 40 (2006), 206–210, 10.1016/j.jpba.2005.07.006.
Maleki, A., Kettiger, H., Schoubben, A., Rosenholm, J.M., Ambrogi, V., Hamidi, M., Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs. J. Control. Release 262 (2017), 329–347, 10.1016/j.jconrel.2017.07.047.
Li, B., Harich, K., Wegiel, L., Taylor, L.S., Edgar, K.J., Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions. Carbohydr. Polym. 92 (2013), 1443–1450, 10.1016/j.carbpol.2012.10.051.
Galano, A., Francisco Marquez, M., Pérez-González, A., Ellagic acid: An unusually versatile protector against oxidative stress. Chem. Res. Toxicol. 27 (2014), 904–918, 10.1021/tx500065y.
J.C. Thermodynamics, J.Z. Dávalos, C.F.R.A.C. Lima, L.M.N.B.F. Santos, V.L. Romero, J.F. Liebman, Thermochemical and structural studies of gallic and ellagic acids, 129 (2019) 108–113. 10.1016/j.jct.2018.09.027.
González-Sarrías, A., García-Villalba, R., Núñez-Sánchez, M.Á., Tomé-Carneiro, J., Zafrilla, P., Mulero, J., Tomás-Barberán, F.A., Espín, J.C., Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts. J. Funct. Foods. 19 (2015), 225–235, 10.1016/j.jff.2015.09.019.
Bala, I., Bhardwaj, V., Hariharan, S., Kharade, S.V., Roy, N., Kumar, M.N.V.R., Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J. Drug Target. 14 (2006), 27–34, 10.1080/10611860600565987.
Hubatsch, I., Ragnarsson, E.G.E., Artursson, P., Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2 (2007), 2111–2119, 10.1038/nprot.2007.303.
Lipińska, L., Klewicka, E., Sójka, M., Structure, occurrence and biological activity of ellagitannins: A general review. Acta Sci. Pol. Technol. Aliment. 13 (2014), 289–299, 10.17306/J.AFS.2014.3.7.
Espín, J.C., Larrosa, M., García-Conesa, M.T., Tomás-Barberán, F., Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: The evidence so far. Evidence-Based Complement. Altern. Med., 2013, 2013, 10.1155/2013/270418.
Giménez-Bastida, J.A., González-Sarrías, A., Larrosa, M., Tomás-Barberán, F., Espín, J.C., García-Conesa, M.T., Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells. Mol. Nutr. Food Res. 56 (2012), 784–796, 10.1002/mnfr.201100677.
Yan, L., Yin, P., Ma, C., Liu, Y., Method development and validation for pharmacokinetic and tissue distributions of ellagic acid using ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Molecules. 19 (2014), 18923–18935, 10.3390/molecules191118923.
Jennotte, O., Koch, N., Lechanteur, A., Evrard, B., Three-dimensional printing technology as a promising tool in bioavailability enhancement of poorly water-soluble molecules: A review. Int. J. Pharm., 580, 2020, 119200, 10.1016/j.ijpharm.2020.119200.
Biopharm Class. sytem.pdf, (n.d.). 10.1023/A:1016212804288.
Kumar, R., Journal of Drug Delivery Science and Technology Nanotechnology based approaches to enhance aqueous solubility and bioavailability of griseofulvin: A literature survey. J. Drug Deliv. Sci. Technol., 53, 2019, 101221, 10.1016/j.jddst.2019.101221.
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm. 420 (2011), 1–10, 10.1016/j.ijpharm.2011.08.032.
Krishnaiah, Y.S., Pharmaceutical Technologies for Enhancing Oral Bioavailability of Poorly Soluble Drugs. J. Bioequiv. Availab. 02 (2010), 28–36, 10.4172/jbb.1000027.
S. Marques, B. Sarmento, Amorphous solid dispersions: Rational selection of a manufacturing process ☆, 100 (2016) 85–101. 10.1016/j.addr.2016.01.012.
H. Jain, N. Chella, Solubility Enhancement Techniques for Natural Product Delivery, 2020. 10.1007/978-3-030-41838-0.
Kanaujia, P., Poovizhi, P., Ng, W.K., Tan, R.B.H., Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs. Powder Technol. 285 (2015), 2–15, 10.1016/j.powtec.2015.05.012.
Ma, X., Iii, R.O.W., J. Drug Deliv. Sci. Technol. Characterizat. Amorphous Solid Dispersions Update 50 (2019), 113–124, 10.1016/j.jddst.2019.01.017.
K. Nagapudi, J. Jona, Amorphous Active Pharmaceutical Ingredients in Preclinical Studies: Amorphous Active Pharmaceutical Ingredients in Preclinical Studies: Preparation, Characterization, and Formulation, (2014). 10.2174/157340708786847852.
He, Y., Ho, C., Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development. J. Pharm. Sci. 104 (2015), 3237–3258, 10.1002/jps.24541.
Tian, Y., Booth, J., Meehan, E., Jones, D.S., Li, S., Andrews, G.P., Construction of drug-polymer thermodynamic phase diagrams using flory-huggins interaction theory: Identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions. Mol. Pharm. 10 (2013), 236–248, 10.1021/mp300386v.
Hens, B., Brouwers, J., Corsetti, M., Augustijns, P., Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. J. Pharm. Sci. 105 (2016), 2677–2684, 10.1002/jps.24690.
Thiry, J., Lebrun, P., Vinassa, C., Adam, M., Netchacovitch, L., Ziemons, E., Hubert, P., Krier, F., Evrard, B., Continuous production of itraconazole-based solid dispersions by hot melt extrusion: Preformulation, optimization and design space determination. Int. J. Pharm. 515 (2016), 114–124, 10.1016/j.ijpharm.2016.10.003.
Gala, U., Miller, D., Williams, R.O., Improved dissolution and pharmacokinetics of abiraterone through kinetisol® enabled amorphous solid dispersions. Pharmaceutics 12 (2020), 1–24, 10.3390/pharmaceutics12040357.
Baghel, S., Cathcart, H., O'Reilly, N.J., Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs. J. Pharm. Sci. 105 (2016), 2527–2544, 10.1016/j.xphs.2015.10.008.
Paudel, A., Worku, Z.A., Meeus, J., Guns, S., Van Den Mooter, G., Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: Formulation and process considerations. Int. J. Pharm. 453 (2013), 253–284, 10.1016/j.ijpharm.2012.07.015.
Y. Liu, C. Sun, Y. Hao, T. Jiang, L. Zheng, S. Wang, Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles, J. Pharm. Pharm. Sci. 13 (2010) 589–606. 10.18433/j3530j.
Psimadas, D., Georgoulias, P., Valotassiou, V., Loudos, G., Molecular Nanomedicine Towards Cancer. J. Pharm. Sci. 101 (2012), 2271–2280, 10.1002/jps.
Haser, A., Huang, S., Listro, T., White, D., Zhang, F., An approach for chemical stability during melt extrusion of a drug substance with a high melting point. Elsevier B.V., 2017, 10.1016/j.ijpharm.2017.03.070.
S.S. Jambhekar, P. Breen, Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex O OH OH OH OH OH HO HO HO O HO OH HO HO HO, 21 (2016).
Del Valle, E.M.M., Cyclodextrins and their uses: A review. Process Biochem. 39 (2004), 1033–1046, 10.1016/S0032-9592(03)00258-9.
Szejtli, J., Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 98 (1998), 1743–1753, 10.1021/cr970022c.
Jacob, S., Nair, A.B., Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev. Res. 79 (2018), 201–217, 10.1002/ddr.21452.
Xu, J., Zhang, Y., Li, X., Zheng, Y., Inclusion complex of nateglinide with sulfobutyl ether β-cyclodextrin: Preparation, characterization and water solubility. J. Mol. Struct. 1141 (2017), 328–334, 10.1016/j.molstruc.2017.03.116.
Maazaoui, R., Abderrahim, R., Applications of cyclodextrins: formation of inclusion complexes and their characterization Radhouan MAAZAOUI and Raoudha ABDERRAHIM * Laboratory of Physics of Lamellaires Materials and Hybrids Nanomaterials, University of Carthage, Faculty of Sciences. Int. J. Adv. Res., 3, 2015, 1030.
Brewster, M.E., Loftsson, T., Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59 (2007), 645–666, 10.1016/j.addr.2007.05.012.
Jansook, P., Ogawa, N., Loftsson, T., Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int. J. Pharm. 535 (2018), 272–284, 10.1016/j.ijpharm.2017.11.018.
E. Pinho, M. Grootveld, M. Henriques, Cyclodextrins as encapsulation agents for plant bioactive compounds, 101 (2014) 121–135. 10.1016/j.carbpol.2013.08.078.
Aranda, C., Urbiola, K., Méndez Ardoy, A., García Fernández, J.M., Ortiz Mellet, C., De Ilarduya, C.T., Targeted gene delivery by new folate-polycationic amphiphilic cyclodextrin-DNA nanocomplexes in vitro and in vivo. Eur. J. Pharm. Biopharm. 85 (2013), 390–397, 10.1016/j.ejpb.2013.06.011.
Adeoye, O., Cabral-Marques, H., Cyclodextrin nanosystems in oral drug delivery: A mini review. Int. J. Pharm. 531 (2017), 521–531, 10.1016/j.ijpharm.2017.04.050.
Lechanteur, Evrard, Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review. Pharmaceutics, 12, 2020, 55, 10.3390/pharmaceutics12010055.
Loftsson, T., Brewster, M.E., Cyclodextrins as functional excipients: Methods to enhance complexation efficiency. J. Pharm. Sci. 101 (2012), 3019–3032, 10.1002/jps.23077.
Yaméogo, J.B.G., Gèze, A., Choisnard, L., Putaux, J.L., Mazet, R., Passirani, C., Keramidas, M., Coll, J.L., Lautram, N., Bejaud, J., Semdé, R., Wouessidjewe, D., Self-assembled biotransesterified cyclodextrins as potential Artemisinin nanocarriers. II: In vitro behavior toward the immune system and in vivo biodistribution assessment of unloaded nanoparticles. Eur. J. Pharm. Biopharm. 88 (2014), 683–694, 10.1016/j.ejpb.2014.08.012.
Crini, G., Review: A history of cyclodextrins. Chem. Rev. 114 (2014), 10940–10975, 10.1021/cr500081p.
Savic, I.M., Jocic, E., Nikolic, V.D., Popsavin, M.M., Srdjan, J., Savic-gajic, I.M., Savic, I.M., Jocic, E., Nikolic, V.D., Popsavin, M.M., The effect of complexation with cyclodextrins on the antioxidant and antimicrobial activity of ellagic acid. Pharm. Dev. Technol. 24 (2019), 410–418, 10.1080/10837450.2018.1502318.
Bulani, V.D., Kothavade, P.S., Nagmoti, D.M., Kundaikar, H.S., Degani, M.S., Juvekar, A.R., Characterisation and anti-inflammatory evaluation of the inclusion complex of ellagic acid with hydroxypropyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 82 (2015), 361–372, 10.1007/s10847-015-0498-7.
Bulani, V.D., Kothavade, P.S., Kundaikar, H.S., Gawali, N.B., Chowdhury, A.A., Degani, M.S., Juvekar, A.R., Inclusion complex of ellagic acid with β-cyclodextrin: Characterization and in vitro anti-inflammatory evaluation. J. Mol. Struct. 1105 (2016), 308–315, 10.1016/j.molstruc.2015.08.054.
Y.N. Chudasama, A. Lugea, Q.Y. Lu, S.J. Pandol, S-860, Gastroenterology. 140 (2005) S-860. 10.1016/S0016-5085(11)63573-7.
F.M. Mady, S. Ragab, M. Ibrahim, Cyclodextrin-based nanosponge for improvement of solubility and oral bioavailability of Ellagic acid, 31 (2018) 2069–2076.
Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J.T., Kim, H., Cho, J.M., Yun, G., Lee, J., Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J. Pharm. Sci. 9 (2014), 304–316, 10.1016/j.ajps.2014.05.005.
Sou, T., Bergström, C.A.S., Physicochemical characterisation in drug discovery Automated assays for thermodynamic (equilibrium) solubility determination. Drug Discov. Today Technol. 27 (2018), 11–19, 10.1016/j.ddtec.2018.04.004.
Savjani, K.T., Gajjar, A.K., Savjani, J.K., Drug Solubility: Importance and Enhancement Techniques. ISRN Pharm. 2012 (2012), 1–10, 10.5402/2012/195727.
R. Shegokar, R.H. Müller, Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives, 399 (2010) 129–139. 10.1016/j.ijpharm.2010.07.044.
Williams, H.D., Trevaskis, N.L., Charman, S.A., Shanker, R.M., Charman, W.N., Pouton, C.W., Porter, C.J.H., Strategies to address low drug solubility in discovery and development. Pharmacol. Rev. 65 (2013), 315–499, 10.1124/pr.112.005660.
Li, Y., Zhao, X., Zu, Y., Zhang, Y., Ge, Y., Zhong, C., Wu, W., Preparation and characterization of micronized ellagic acid using antisolvent precipitation for oral delivery. Int. J. Pharm. 486 (2015), 207–216, 10.1016/j.ijpharm.2015.03.071.
Montes, A., Wehner, L., Pereyra, C., Martínez De La Ossa, E.J., Generation of microparticles of ellagic acid by supercritical antisolvent process. J. Supercrit. Fluids. 116 (2016), 101–110, 10.1016/j.supflu.2016.05.019.
Y.-I. Jeong, R.P. Yv, T. Ohno, Y. Yoshikawa, N. Shibata, S. Kato, K. Takeuchi, K. Takada, Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine, J. Pharm. Pharmacol. 53 (2001) 1079–1085. 10.1211/0022357011776469.
Alfei, S., Turrini, F., Catena, S., Zunin, P., Parodi, B., Zuccari, G., Pittaluga, A.M., Boggia, R., Preparation of ellagic acid micro and nano formulations with amazingly increased water solubility by its entrapment in pectin or non-PAMAM dendrimers suitable for clinical applications. New J. Chem. 43 (2019), 2438–2448, 10.1039/C8NJ05657A.
Bala, I., Bhardwaj, V., Hariharan, S., Sitterberg, J., Bakowsky, U., Ravi Kumar, M.N.V., Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16 (2005), 2819–2822, 10.1088/0957-4484/16/12/014.
Mady, F.M., Shaker, M.A., Enhanced anticancer activity and oral bioavailability of ellagic acid through encapsulation in biodegradable polymeric nanoparticles. Int. J. Nanomed. 12 (2017), 7405–7417, 10.2147/IJN.S147740.
Ruan, J., Yang, Y., Yang, F., Wan, K., Fan, D., Wang, D., Novel oral administrated ellagic acid nanoparticles for enhancing oral bioavailability and anti-inflammatory efficacy. J. Drug Deliv. Sci. Technol. 46 (2018), 215–222, 10.1016/j.jddst.2018.05.021.
Wu, L., Zhang, J., Watanabe, W., Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 63 (2011), 456–469, 10.1016/j.addr.2011.02.001.
Crum, M.F., Trevaskis, N.L., Williams, H.D., Pouton, C.W., Porter, C.J.H., A new in vitro lipid digestion - In vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations. Pharm. Res. 33 (2016), 970–982, 10.1007/s11095-015-1843-7.
Pouton, C.W., Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and “self-microemulsifying” drug delivery systems. Eur. J. Pharm. Sci. 11 (2000), 93–98, 10.1016/S0928-0987(00)00167-6.
Pouton, C.W., Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29 (2006), 278–287, 10.1016/j.ejps.2006.04.016.
Kalepu, S., Manthina, M., Padavala, V., Oral lipid-based drug delivery systems – an overview. Acta Pharm. Sin. B. 3 (2013), 361–372, 10.1016/j.apsb.2013.10.001.
Mu, H., Holm, R., Müllertz, A., Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm. 453 (2013), 215–224, 10.1016/j.ijpharm.2013.03.054.
Pouton, C.W., Porter, C.J.H., Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv. Drug Deliv. Rev. 60 (2008), 625–637, 10.1016/j.addr.2007.10.010.
C. Gu, H. Li, J. Levons, K. Lentz, R.B. Gandhi, K. Raghavan, R.L. Smith, Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties, 24 (2007) 1118–1130. 10.1007/s11095-007-9236-1.
A. Müllertz, A. Ogbonna, S. Ren, New perspectives on lipid and surfactant based drug, (2010) 1622–1636. 10.1111/j.2042-7158.2010.01107.x.
Chen, X.Q., Gudmundsson, O.S., Hageman, M.J., Application of lipid-based formulations in drug discovery. J. Med. Chem. 55 (2012), 7945–7956, 10.1021/jm3006433.
Savla, R., Browne, J., Plassat, V., Wasan, K.M., Wasan, E.K., Review and analysis of FDA approved drugs using lipid-based formulations. Drug Dev. Ind. Pharm. 43 (2017), 1743–1758, 10.1080/03639045.2017.1342654.
Wang, S.T., Te Chou, C., Su, N.W., A food-grade self-nanoemulsifying delivery system for enhancing oral bioavailability of ellagic acid. J. Funct. Foods. 34 (2017), 207–215, 10.1016/j.jff.2017.04.033.
Avachat, A.M., Patel, V.G., Self nanoemulsifying drug delivery system of stabilized ellagic acid-phospholipid complex with improved dissolution and permeability. Saudi Pharm. J. 23 (2015), 276–289, 10.1016/j.jsps.2014.11.001.
Murugan, V., Mukherjee, K., Maiti, K., Mukherjee, P.K., Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. J. Agric. Food Chem. 57 (2009), 4559–4565, 10.1021/jf8037105.
Zheng, D., Lv, C., Sun, X., Wang, J., Zhao, Z., Preparation of a supersaturatable self-microemulsion as drug delivery system for ellagic acid and evaluation of its antioxidant activities. J. Drug Deliv. Sci. Technol., 53, 2019, 101209, 10.1016/j.jddst.2019.101209.
Ayad, M.H., Rational formulation strategy from drug discovery profiling to human proof of concept. Drug Deliv. 22 (2015), 877–884, 10.3109/10717544.2014.898714.
Salmani, J.M.M., Lv, H., Asghar, S., Zhou, J., Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: A successful approach to improve the bioavailability of atorvastatin. Pharm. Dev. Technol. 20 (2015), 465–472, 10.3109/10837450.2014.882938.
Li, J., Lee, I.W., Shin, G.H., Chen, X., Park, H.J., Curcumin-Eudragit® e PO solid dispersion: A simple and potent method to solve the problems of curcumin. Eur. J. Pharm. Biopharm. 94 (2015), 322–332, 10.1016/j.ejpb.2015.06.002.
Hughey, J.R., Keen, J.M., Brough, C., Saeger, S., McGinity, J.W., Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: The utility of KinetiSol ® Dispersing. Int. J. Pharm. 419 (2011), 222–230, 10.1016/j.ijpharm.2011.08.007.
Ellenberger, D.J., Miller, D.A., Williams, R.O., Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol®: a Review. AAPS PharmSciTech. 19 (2018), 1933–1956, 10.1208/s12249-018-1007-2.
Hasa, D., Voinovich, D., Perissutti, B., Grassi, G., Fiorentino, S., Farra, R., Abrami, M., Colombo, I., Grassi, M., Reduction of melting temperature and enthalpy of drug crystals: Theoretical aspects. Eur. J. Pharm. Sci. 50 (2013), 17–28, 10.1016/j.ejps.2013.03.018.
Zili, Z., Sfar, S., Fessi, H., Preparation and characterization of poly-ε-caprolactone nanoparticles containing griseofulvin. Int. J. Pharm. 294 (2005), 261–267, 10.1016/j.ijpharm.2005.01.020.
Kumar, R., Nanotechnology based approaches to enhance aqueous solubility and bioavailability of griseofulvin: A literature survey. J. Drug Deliv. Sci. Technol., 53, 2019, 101221, 10.1016/j.jddst.2019.101221.
Thiry, J., Krier, F., Evrard, B., A review of pharmaceutical extrusion: Critical process parameters and scaling-up. Int. J. Pharm. 479 (2015), 227–240, 10.1016/j.ijpharm.2014.12.036.